SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Yari M) "

Sökning: WFRF:(Yari M)

  • Resultat 1-4 av 4
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  • Oskooi, Behrooz, et al. (författare)
  • Attenuation of random noise in GPR data by image processing
  • 2018
  • Ingår i: Arabian Journal of Geosciences. - Heidelberg : Springer. - 1866-7511 .- 1866-7538. ; 11:21
  • Tidskriftsartikel (refereegranskat)abstract
    • Random noise in ground penetrating radar (GPR) data affects the signal-to-noise ratio, blurs the details, and complicates reconnaissance of the useful information. Many methods with different advantages and disadvantages have been proposed to eliminate or weaken the random noise. We have reviewed basic principles of various signal processing techniques including the curvelet transform (CT), non-local mean (NLM), median, and mean filters to remove the random noise and compared their performances using synthetic and actual GPR data. The performances of the four filters were analyzed on synthetic GPR data both in time and frequency domains. On noisy synthetic data, results indicate that the CT filter performs better than NLM, mean, and median filters at attenuating random noise and improving S/N of the GPR data. On the real data, the performance of only the NLM and CT filters was investigated. Comparing the results clearly shows the CT filter robustness for the random noise attenuation and simultaneously its signal preservation
  •  
4.
  • Prudencio, Mercedes, et al. (författare)
  • Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3
  • 2020
  • Ingår i: Science Translational Medicine. - : American Association for the Advancement of Science (AAAS). - 1946-6242 .- 1946-6234. ; 12:566
  • Tidskriftsartikel (refereegranskat)abstract
    • Spinocerebellar ataxia type 3 (SCA3), caused by a CAG repeat expansion in the ataxin-3 gene (ATXN3), is characterized by neuronal polyglutamine (polyQ) ATXN3 protein aggregates. Although there is no cure for SCA3, gene-silencing approaches to reduce toxic polyQ ATXN3 showed promise in preclinical models. However, a major limitation in translating putative treatments for this rare disease to the clinic is the lack of pharmacodynamic markers for use in clinical trials. Here, we developed an immunoassay that readily detects polyQ ATXN3 proteins in human biological fluids and discriminates patients with SCA3 from healthy controls and individuals with other ataxias. We show that polyQ ATXN3 serves as a marker of target engagement in human fibroblasts, which may bode well for its use in clinical trials. Last, we identified a single-nucleotide polymorphism that strongly associates with the expanded allele, thus providing an exciting drug target to abrogate detrimental events initiated by mutant ATXN3. Gene-silencing strategies for several repeat diseases are well under way, and our results are expected to improve clinical trial preparedness for SCA3 therapies.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-4 av 4

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy